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Abstract
Background: Encephalitis with anti-N-methyl-D-aspartate receptor antibodies (anti-NMDAR-Ab) is a rapid-onset
encephalitis including psychosis, seizures, various movement disorders and autonomic system disturbances.
Case presentation: We report a very unusual case of extensive myelitis associated with anti-NMDAR-Ab. MRI also
revealed a hyperintense T2 lesion, non-suggestive of MS, which progressively extended, associated with periventricular
gadolinium enhancement visualized on brain MRI. Ophthalmological evaluation showed subclinical right optic neuritis.
The absence of anti-AQP4 antibody argued against neuromyelitis optica spectrum disorder. A slight psychomotor
slowing prompted us to search for various causes of autoimmune encephalitis. Anti-NMDAR-Ab was found in
cerebrospinal fluid.
Conclusion: In patients with extensive myelitis who are seronegative for anti-AQP4 antibodies, and after other classical
causes have been excluded, the hypothesis of atypical anti-NMDAR-Ab encephalitis should also be considered.
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Background
Encephalitis with anti-N-methyl-D-aspartate receptor anti-
bodies (anti-NMDAR-Ab) is a rapid-onset encephalitis
including psychosis, seizures, various movement disorders
and autonomic system disturbances. The physiopathology
is based on immune-mediated neuronal dysfunction [1,2].
We report the case of a 65-year-old woman presenting an
extensive myelitis associated with anti-NMDAR-Ab.
Case presentation
A 65-year-old woman was admitted because of progressive
paraparesis (June 2012). Six months before admission, she
had presented with fever, chills, abdominal pain and un-
usual headache for one week with spontaneous recovery.
Abdomen and brain MRI were normal at that time. Two
months before admission, she described a progressive on-
set of walking difficulties. At the same time, constipation
and dysuria were noted. At her admission, neurological
examination noted walking difficulties related to moderate
paraparesis, moderate superficial and deep sensory
dysfunction of the lower limbs and urinary retention. A
very slight dysfunction of mental processing without
speech disturbance was noted and confirmed by her
family. No seizures, dyskinesia, movement disorders,
psychiatric symptoms or autonomic dysfunction were
observed.
Spinal cord MRI showed longitudinally extensive mye-
litis from C5 to T10 with gadolinium (Gd) enhancement
(Figure 1A,B). Brain MRI follow-up showed T2 hyperin-
tensities within the insular regions, medial temporal lobes
and thalamus (Figure 1C), associated with gadolinium en-
hancement of the meninges and ventricles (Figure 1D).
Analysis of the cerebrospinal fluid (CSF) showed moderate
lymphocytic pleocytosis (53 cells/mm3), mild increased
protein concentration (0.91 g/L) and oligoclonal bands.
PCR assays for herpesviridae in CSF were all negative.
Ophthalmological examination showed delayed P100 la-
tencies on the right side on visual evoked potentials and
asymmetric global retinal nerve fibre layer (RNFL)
thicknesses on optical coherence tomography (OCT)
suggestive of asymptomatic right optic neuritis (ON).
OCT analyses were both perfectly centred on the optic
nerve head (Figure 1E). Tests for anti-aquaporin 4
(AQP4) antibodies (Ab) in serum were negative. EEG
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showed slow and discontinuous activity in the left
fronto-temporal regions. Extensive tests for auto-Ab
(anti-onconeuronal, anti-DNA, anti-phospholipid, anti-
voltage-gated potassium channel, anti-glutamate acid
decarboxylase) were negative except for anti-NMDAR-
Ab (IgG isotype) in the CSF and serum. No cancer was
found (gynaecological examination, pelvic ultrasonog-
raphy and MRI, mammography, total-body computed
tomography scan and positron emission tomography
scan were all normal).
Intravenous corticosteroids (1 g per day during 3 days
plus 5 days) were given but the paraparesis worsened
A
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Figure 1 Spinal cord, brain and optical imaging follow-up of the patient. June 2012: Spinal cord magnetic resonance imaging (MRI)
showing extensive hyper intense T2 lesion between C5 and T10 (A) with gadolinium enhancement on T1 sequence (B). Brain MRI showing
multiple hyperintense T2 lesions on insular regions, medial temporal lobes and thalamus (C), but also gadolinium enhancement of ventricles and
meninges (D). Peripapillary optical coherence tomography showing asymmetric retinal nerve fiber layer (E). July 2012: Control brain MRI showing
extension of hyperT2 lesion load (F).
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(bedridden patient). Brain and spinal cord MRIs follow-up
(July 2012) showed an extension of T2 lesions without Gd
enhancement (Figure 1F) and a stable extensive T2 lesion
without Gd enhancement, respectively. As soon as anti-
NMDAR-Ab were detected, plasma exchanges (PLEX)
were initiated and followed by intravenous rituximab
(375 mg/m2 every week for 4 weeks) plus tapering oral
corticosteroids (1 mg/kg). Brain and spinal cord MRIs
follow-up (August 2012) showed the disappearance of
the extensive spinal cord T2 lesion and stable cerebral
T2 lesions. Biological follow-up of anti-NMDAR-Ab
rates in CSF and serum was performed (Table 1). CSF
analysis was weakly positive just after corticosteroids/
PLEX (M1) and was negative 2 months after rituximab
(M3). Serum analysis was less correlated to clinical
status. Four months after the inaugural myelitis, there
was a significant improvement of the paraparesis (the
patient was able to walk for 5 metres with bilateral sup-
port) and a total regression of the slight psychomotor
retardation was observed. Unfortunately, the patient
presented rapidly evolving pneumocystis pneumonia at
this time and she died of respiratory failure. Autopsy
was not performed.
Discussion
Our patient presented extensive myelitis associated with
anti-NMDAR-Ab leading us to discuss a possible atyp-
ical form of anti-NMDAR-Ab encephalitis. Spinal cord
symptoms were prominent throughout the clinical stage
and were consistent with the extensive myelitis detected
on spinal cord MRI. Slight psychomotor retardation is
not sufficient to affirm that our patient presented anti-
NMDAR-Ab encephalitis but early treatment might have
stopped its development. Brain MRI showed hyperin-
tense T2 lesions but also ventriculitis aspect. In view of
the combination of extensive myelitis, brain T2 lesions
non-suggestive of MS, ventriculitis aspect on MRI and
subclinical ON, our first hypothesis was myelitis as a
first event of neuromyelitis optica (NMO) or NMO
spectrum disorder (NMOSD). Although cognitive distur-
bances are described in NMO [3], we also looked for
other conditions involving auto-immune encephalitis
and found anti-NMDAR-Ab in the CSF before immuno-
suppressive drugs had been applied.
Prodromal symptoms such as headache and fever are
common [1] but we noted 3 atypical events for the hy-
pothesis of anti-NMDAR-Ab encephalitis. First, myelitis
is a very rare manifestation during anti-NMDAR-Ab en-
cephalitis but has already been described [4-6]. In these
3 previous cases, all patients presented severe psychiatric
or behavioural symptoms before the spinal cord syn-
drome and the encephalopathic symptoms remained
prominent during all stages of the disease. In our case,
the spinal cord syndrome remained prominent from the
beginning and extension of the hyperintense T2 lesion
was greater. Secondly, we highlighted in our case ventri-
culitis associated with meningeal Gd enhancement.
Meningeal contrast enhancement in anti-NMDAR-Ab
encephalitis is rare and [7,8], to the best of our know-
ledge, the ventriculitis aspect has never previously been
described. NMDA receptors are membrane receptors
widely expressed in the central nervous system on vari-
ous cells such as neurons, oligodendrocytes but also
astrocytes [9]. The ependymal regions contain epen-
dymal cells and astrocytes rich in AQP4, and can also be
involved in NMO, as described in 2 previously reported
cases with thin ependymal and periventricular Gd en-
hancement [10,11]. Thirdly, our patient presented right
subclinical ON. Since the prodromal symptoms dated
back 6 months, it seems likely that the demyelinating
pathology had already started 6 months before the spinal
cord syndrome. RNFL atrophy most often (>94 %) ap-
pears within the 6 months after ON [12]. ON has only
once been reported as a neurological manifestation of
anti-NMDAR-Ab encephalitis [13].
Even though some correlations have been found be-
tween clinical status and anti-NMDAR-Ab titres in CSF,
there is no reported correlation with anti-NMDAR-Ab
titres in serum, and we therefore do not recommend a
follow-up of anti-NMDAR-Ab titres in serum [1,14].
Anti-NMDAR-Ab encephalitis has been described fol-
lowing massive brain damage induced by herpes simplex
Table 1 Anti-NMDA-R follow-up of the titration in CSF and in serum (qualitative and quantitative)
Date Jun
23rd
Jul
2nd
Jul
10th
Jul
11th
Jul
14th
Jul
16th
Jul
17th
Jul
23rd
Jul
30th
Aug
6th
Aug
13th
Oct
17th
CSF + (1/10) + (low) NA NA NA NA - NA NA NA NA -
Anti-NMDA-R in serum NA NA + (1/10) + (1/10) - + (low) - - + (low) NA + (1/10) -
Methylprednisolone
(1 g/day IV)
3 days 5 days
PLEX Yes Yes Yes Yes Yes
Rituximab (375 mg/m2/week
during 4 weeks)
Yes Yes Yes Yes
Jun, June; Jul, July; Aug, August; Oct, October; CSF, cerebrospinal fluid; NA, not available; PLEX, plasma exchange; 5 PLEX were performed followed by infusions of
rituximab (375 mg/m2/week during 4 weeks).
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encephalitis (HSE) [15,16]. Anti-NMDAR-Ab has also
been found in sera of systemic lupus erythematosus and
might be predictive of neuropsychiatric manifestations
[17]. In the present case report, we cannot affirm that
our patient presented anti-NMDAR-Ab encephalitis be-
cause of encephalopathic symptoms lacking and also
cannot exclude that a massive brain and spinal damage
of unknown etiology has led to secondary immuno-
logical response with anti-NMDA-R Ab production.
We can also discuss the hypothesis that our patient may
have presented 2 auto-immune diseases concurrently: an
NMOSD and an anti-NMDAR-Ab encephalitis. These are
both Ab-mediated diseases and a comorbid association of
auto-immune diseases is possible. Recently a case of NMO
(seropositive anti-AQP4 Ab) following anti-NMDAR-Ab
encephalitis has been described [18]. As our patient was
seronegative for anti-AQP4 Ab and presented only subclin-
ical ON, we cannot conclusively confirm or rule out this
hypothesis.
Conclusion
In patients with extensive myelitis who are seronegative
for anti-AQP4 Ab, and after other classical causes have
been excluded, the hypothesis of atypical anti-NMDAR-
Ab encephalitis should also be considered.
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